Palifosfamide-tris 联合卡铂和依托泊苷治疗未接受过化疗的广泛期小细胞肺癌患者的研究(MATISSE 研究)
一项多中心、开放标签、适应性、随机研究,一种新型 DNA 交联剂 Palifosfamide-tris 联合卡铂和依托泊苷 (PaCE) 化疗与单独使用卡铂和依托泊苷 (CE) 相比,用于未接受过化疗的广泛期小患者细胞肺癌。马蒂斯研究
This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of palifosfamide-tris, carboplatin and etoposide (PaCE) chemotherapy in chemotherapy-naive subjects with extensive-stage small cell lung cancer (SCLC). Eligible subjects will be stratified according to age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status, and randomized in a 1:1 ratio to receive either PaCE or carboplatin and etoposide (CE) chemotherapy.
The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis.
Secondary efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), duration of response and changes in quality of life (QOL) and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.
The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed.
An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Haifa、以色列
- Rambam Medical Center
-
Jerusalem、以色列、91120
- Hadassah Medical Organization, Ein Kerem
-
Kfar Saba、以色列
- Meir Hospital Sapir Medical Center
-
Nahariya、以色列、22100
- Western Gallilee Medical Center
-
Petah Tikva、以色列、49100
- Rabin Medical Center Beilinson Campus
-
-
-
-
-
Chelaybinsk、俄罗斯、454087
- State Budget Institution of Healthcare "Chelyabinsk Regional Clinical Oncology Dispensary"
-
Ivanovo、俄罗斯
- Ivanovo Regional Oncology Centre
-
Moscow、俄罗斯
- Cancer Research Center n.a. N.N. Blokhin
-
Nizhny Novgorod、俄罗斯、603081
- GUZ of Nizhegorodskiy region, Nizhnij Novgorod City Oncology Dispensary
-
Saint Petersburg、俄罗斯、194044
- State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
-
Saint Petersburg、俄罗斯
- Saint-Petersburg State Medical University n. a. I. P. Pavlov
-
Yaroslavl、俄罗斯、150040
- State healthcare institution of Yaroslavl region "Regional Clinical Oncologic Hospital"
-
-
Bashkortostan Republic
-
Ufa、Bashkortostan Republic、俄罗斯、450054
- Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
-
-
Moscow
-
Moscow Region、Moscow、俄罗斯、143423
- City Oncology Hospital # 62
-
-
Primorskiy (Maritime) Kray
-
Arkhangelsk、Primorskiy (Maritime) Kray、俄罗斯、163045
- State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
-
-
Tatarstan Republic
-
Kazan'、Tatarstan Republic、俄罗斯
- Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
-
-
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3E 0V9
- CancerCare Manitoba
-
-
Ontario
-
Oshawa、Ontario、加拿大、L1G 2B9
- R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
-
-
Quebec
-
Sainte-Foy、Quebec、加拿大、G1V 4G5
- Hôpital Laval
-
-
-
-
Hajdú-Bihar
-
Debrecen、Hajdú-Bihar、匈牙利
- Debreceni Egyetem Orvos és Egészségtudományi Centrum
-
-
Heves County
-
Mátraháza、Heves County、匈牙利
- Mátrai Gyógyintézet
-
-
-
-
-
Taichung、台湾、40447
- China Medical University Hospital
-
-
-
-
-
Genova、意大利
- Istituto Nazionale per la Ricerca sul Cancro
-
Milan、意大利、20162
- Azienda Ospedaliera Ospedale Niguarda Ca' Granda
-
Trento、意大利、38100
- Presidio Ospedaliero S. Chiara
-
-
-
-
-
Strasbourg、法国、67085
- Centre Paul Strauss
-
-
Auvergne-Rhône-Alpes
-
Pierre Bénité、Auvergne-Rhône-Alpes、法国、69495
- Centre Hospitalier Lyon Sud
-
-
Basse-normandie
-
Caen、Basse-normandie、法国、14076
- Centre François Baclesse
-
-
Brittany Region
-
Brest、Brittany Region、法国、29200
- Centre Hospitalier Universitaire -Hôpital Morvan
-
-
Centre-Val de Loire
-
Tours、Centre-Val de Loire、法国、97044
- Centre Hospitalier Universitaire, Hopital Bretonneau
-
-
Limousin, Lorraine
-
Limoges、Limousin, Lorraine、法国、87042
- Hôpital du Cluzeau
-
-
Pays de la Loire Region
-
Saint-Herblain、Pays de la Loire Region、法国、44805
- Institut de Cancérologie de l'Ouest - René Gauducheau
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille、Provence-Alpes-Côte d'Azur Region、法国、13008
- Hôpital Saint Joseph
-
-
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、波兰
- Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie
-
-
Pomeranian Voivodeship
-
Gdansk、Pomeranian Voivodeship、波兰
- Uniwersyteckie Centrum Kliniczne
-
Gdansk、Pomeranian Voivodeship、波兰
- Wojewódzkie Centrum Onkologii
-
-
West Pomeranian Voivodeship
-
Szczecin、West Pomeranian Voivodeship、波兰
- Specjalistyczny Szpital im. Alfreda Sokolowskiego
-
-
-
-
New South Wales
-
Wollongong、New South Wales、澳大利亚、2500
- Southern Medical Day Oncology Care Centre
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35205
- Birmingham Hematology and Oncology Associates, LLC
-
-
California
-
Los Angeles、California、美国、90033
- University of Southern California
-
Santa Rosa、California、美国、95403
- Redwood Regional Oncology Group
-
-
Delaware
-
Newark、Delaware、美国、19713
- Christiana Care Health Services
-
-
Florida
-
Jacksonville、Florida、美国、32207
- Baptist Cancer Institute
-
Port Saint Lucie、Florida、美国、34952
- Hematology Oncology Associates of the Treasure Coast
-
-
Georgia
-
Atlanta、Georgia、美国、30318
- Peachtree Hematology Oncology Consultants
-
-
Illinois
-
Chicago、Illinois、美国、60612
- Rush University Medical Center
-
Galesburg、Illinois、美国、61401
- Medical and Surgical Specialists, LLC
-
Niles、Illinois、美国、60714-5905
- Illinois Cancer Specialists
-
-
Indiana
-
Fishers、Indiana、美国、46037
- Central Indiana Cancer Centers
-
Goshen、Indiana、美国、46526
- Goshen Center for Cancer Care
-
Indianapolis、Indiana、美国、46202
- Indiana University
-
Lafayette、Indiana、美国、47905
- Horizon Oncology Center
-
Muncie、Indiana、美国、47303
- Indiana University Health Ball Memorial Hospital
-
-
Kansas
-
Overland Park、Kansas、美国、66210
- University of Kansas Hospital
-
-
Kentucky
-
Lexington、Kentucky、美国、40503
- Central Baptist Hospital
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70809
- Medical Oncology, LLC
-
-
Maryland
-
Frederick、Maryland、美国、21701
- Frederick Memorial Hospital Regional Cancer Therapy Center
-
-
Michigan
-
Wyoming、Michigan、美国、49519
- Metro Health Cancer Center
-
-
Minnesota
-
Duluth、Minnesota、美国、55805
- Saint Mary's Medical Center
-
Minneapolis、Minnesota、美国、55407
- Virginia Piper Cancer Institute
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- John Theurer Cancer Center at Hackensack University Medical Center
-
Morristown、New Jersey、美国、07962
- Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany、New York、美国、12110-2188
- New York Oncology Hematology, PC
-
The Bronx、New York、美国、10461
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- The Christ Hospital
-
Dayton、Ohio、美国、45429
- Dayton Cancer Center, Medical Oncology Hematology Associates
-
-
Pennsylvania
-
Kingston、Pennsylvania、美国、18704
- Medical Oncology Associates Of Wyoming Valley, PC
-
-
South Carolina
-
Charleston、South Carolina、美国、29403
- Charleston Hematology Oncology Associates, PA
-
-
Texas
-
Dallas、Texas、美国、75230-6899
- Texas Oncology-Medical City Dallas
-
Dallas、Texas、美国、75246
- Texas Oncology- Baylor, Charles A. Sammons Cancer Center
-
Galveston、Texas、美国、77555-0565
- University of Texas Medical Branch at Galveston
-
Houston、Texas、美国、77024
- Oncology Consultants, PA
-
Wichita Falls、Texas、美国、76310-1610
- Texas Oncology, PA
-
-
Vermont
-
Burlington、Vermont、美国、05405
- Fletcher Allen Health Care
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- Fairfax Northern Virginia Hematology-Oncology, PC
-
-
Washington
-
Seattle、Washington、美国、98104
- Swedish Medical Center
-
-
Wisconsin
-
Madison、Wisconsin、美国、53705
- Wisconsin Institutes for Medical Research
-
-
-
-
England
-
Manchester、England、英国、M23 9LT
- Wythenshawe Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Documented extensive-stage small cell lung cancer.
- Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
- Male and female patients must agree to use a highly reliable method of birth control during study participation.
- Able to provide informed consent
Exclusion Criteria:
- Previously untreated (non-irradiated), symptomatic brain metastases.
- Known allergy to any of the study drugs or their excipients.
- Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
- Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
- Currently pregnant or nursing.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Palifosfamide-tris plus Carboplatin and Etoposide
Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles. |
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles. |
|
有源比较器:Carboplatin plus Etoposide
Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. |
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
总生存期(OS)
大体时间:每 12 周评估一次生存情况,直至完成注册后 1 年
|
每 12 周评估一次生存情况,直至完成注册后 1 年
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
无进展生存期 (PFS)
大体时间:每 6 周评估一次,持续 22 周,然后每 12 周评估一次,直到疾病进展、开始替代抗癌治疗或最后一名患者入组后 1 年(以较早者为准)
|
每 6 周评估一次,持续 22 周,然后每 12 周评估一次,直到疾病进展、开始替代抗癌治疗或最后一名患者入组后 1 年(以较早者为准)
|
|
客观缓解率 (ORR)
大体时间:每 6 周评估一次,持续 22 周,然后每 12 周评估一次,直到确认部分或完全缓解
|
每 6 周评估一次,持续 22 周,然后每 12 周评估一次,直到确认部分或完全缓解
|
|
响应持续时间
大体时间:从第一次客观反应(部分或完全反应),随后确认,到疾病进展或死亡发生之日的时间
|
从第一次客观反应(部分或完全反应),随后确认,到疾病进展或死亡发生之日的时间
|
|
Quality of Life (QOL) as Assessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)
大体时间:Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
|
Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
|
|
Safety Parameters (Adverse Events and Number of Findings: Physical Examinations, Electrocardiograms [ECGs], Vital Signs, and Clinical Laboratory Results) Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 4.03
大体时间:22 weeks
|
22 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.